Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
about
The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesB Cells and Autoantibodies in Multiple SclerosisTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesHistopathology and clinical course of MOG-antibody-associated encephalomyelitisChildren with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseasesAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosisMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeMyelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.B lymphocytes in neuromyelitis opticaMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.Multiple sclerosis: experimental models and reality.Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?Neuromyelitis optica: a positive appraisal of seronegative cases.Experimental models of neuromyelitis optica: current status, challenges and future directions.An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future.What's new in neuromyelitis optica? A short review for the clinical neurologist.Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.Mechanisms for lesion localization in neuromyelitis optica spectrum disorders.Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response
P2860
Q26767391-DC25DD76-396B-4890-919E-BBDBF5AA4E32Q26801386-6D8EF00D-53DD-46CB-8298-3E10E82356F3Q28245749-EF474629-4A62-4E58-A886-13039941112BQ28259551-D95C0583-8F79-40AB-B060-72F091FCA710Q28273255-47BE6198-2CB8-4204-9B4C-EF132AEA5CC4Q29036090-362AD0C3-88C8-436C-9D30-C12947820F9CQ30371412-755A4540-E25A-4661-9116-874631ED53EBQ33645795-87FA567E-7526-4159-80F0-6F66B3B91DA7Q34486841-A097E608-C2F1-45D8-99EE-BAAFBFD9CE7BQ34513731-D90D7F3C-67CE-4A20-A8DA-B571D5953D94Q35591039-A7041C31-31D2-4567-BC78-30A9E5341D1BQ37374434-DC960653-10B7-4A2E-BE6C-B1A081F685B4Q37383474-A3321313-BF89-477F-B538-D9065C0A993DQ37383555-065ABB02-8860-4A15-B049-8E382F1889D8Q37402026-6A213B48-342F-499E-94A5-B1ED66517558Q37470003-6946DECE-3D6D-4632-BF07-D4E2A9651F81Q37590294-E2F656BE-077C-456F-9611-1C0E2520E706Q37596784-C86C7357-0559-4D43-869A-826CAD28D697Q38337465-5CAFDBB5-3018-4A9E-A2A1-52B264FA8F9CQ38358675-8B3F0F7F-4DE2-4EDD-9C85-7DBDFE6F802DQ38537409-57780232-212D-461A-B991-C9C242769C0FQ38652593-CA9CAC89-72A9-4A31-8D10-1C57F675E7A4Q39176987-F65CB1C8-9793-474E-86DE-F0A4940EE11EQ40545113-2C0ABE7B-911E-4569-A273-EC9A0370F48CQ42627948-AE3F57F2-9091-438C-8C8E-46F1FFDEC081Q42844764-B02D7E98-EC4D-4008-99DD-32A1B1E39BB5Q48605549-29EDC85A-7AF3-474A-943F-0ED4A2A07453Q49713173-1B85728F-155F-4BE4-9CB5-9E4AC904257BQ52152221-7B35EDEC-1D61-48D9-AF3D-6681E5D1F154Q56673306-5437BF27-563E-4EC4-9EBE-C4195E1F1295
P2860
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@en
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@nl
type
label
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@en
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@nl
prefLabel
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@en
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@nl
P2093
P2860
P50
P356
P1476
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
@en
P2093
Angela Vincent
Gregory P Owens
Jeffrey L Bennett
P2860
P2888
P356
10.1186/2051-5960-2-35
P577
2014-03-31T00:00:00Z
P5875
P6179
1034400981